An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Trial Profile

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESONATE-2
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 28 Sep 2015 Treatment arm changed from one arm to 4 arms, Alternative anticancer therapy added as reported by ClinicalTrials.gov.
    • 28 Sep 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Feb 2018 as reported by ClinicalTrials.gov
    • 28 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top